Scotch Plains, NJ, United States of America

Peter T Meinke

This inventor holds 25 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Pharmaceutical Compositions. Top assignees: Merck + Co., Inc., Merck Sharp + Dohme Corp., Tri-Institutional Therapeutics Discovery Institute. Active years: 1992-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Peter T Meinke. Retrieved from https://idiyas.com/inventor/peter-t-meinke

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 25 

% Patents Active = 76.0

 

 

Average Co-Inventor Count = 3.2

ph-index = 5

Forward Citations = 69(Granted Patents)


Location History:

  • New York, NY (US) (1992 - 2001)
  • Plainfield, NJ (US) (2002 - 2008)
  • Scotch Plains, NJ (US) (2009 - 2012)
  • Scotch Plains, NY (US) (2024)

Company Filing History:


Years Active: 1992-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Pyrrolo Compounds
PI3K Inhibitors
Avermectin Derivatives
Ocular Hypertension
Thiazolidinediones
Oxazolidinediones
Indoles
Cyclic Tetrapeptides
Nodulisporic Acid
Sodium Channel Blockers
Antidiabetic Agents
Antiprotozoal Agents
25 patents (USPTO):Explore Patents

Title: Inventions and Innovations of Peter T Meinke

Introduction

Peter T Meinke is a prolific inventor based in Scotch Plains, NJ, who has been granted 22 patents throughout his career. His work primarily focuses on the development of innovative compounds that address significant health issues, particularly in the field of diabetes and inflammation.

Latest Patents

Among his latest inventions is a patented method of treatment utilizing fused aromatic compounds that exhibit anti-diabetic activity. These fused aromatic compounds serve as PPAR gamma agonists or partial agonists, offering a promising approach for weekly dosing in managing type II diabetes and its associated conditions, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity.

Another significant patent concerns p38 kinase inhibiting agents. The compounds outlined in this patent, described by a specific chemical formula or their pharmaceutically acceptable salts, demonstrate efficacy as inhibitors of p38. They are valuable in treating various inflammatory conditions, including asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), rheumatoid arthritis, and several skin and eye conditions associated with inflammation.

Career Highlights

Peter has held positions in well-known pharmaceutical companies, notably Merck & Company, Inc. and Merck Sharp & Dohme Corporation. His tenure in these organizations allowed him to contribute extensively to the research and development of therapeutic agents that tackle complex health challenges.

Collaborations

Throughout his career, Peter has had the opportunity to work alongside notable colleagues, including Michael H Fisher and Helmut H Mrozik. Their collaboration has undoubtedly enriched his research efforts and led to advancements in the pharmaceutical field.

Conclusion

With a robust portfolio of patents and groundbreaking innovations, Peter T Meinke continues to make significant contributions to health care through his inventions. His work serves as a testament to the power of innovation in addressing some of the most pressing medical challenges today.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…